Company Management  
Contact Us  
Lanfear Capital's current portfolio of investments demonstrates our commitment to partner with entrepreneurs to create value. We are proud of our portfolio companies and we are pleased with the working relationships that we have developed with Board members and management teams.

InteKrin Therapeutics, Inc.  
  InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. InteKrin Tehrateurics, Inc.
Saronyx, Inc.  
  Saronyx Inc., provides decision support and workflow integration tools for drug development program management. A bottom-up approach embracing best practices is integrated with powerful top-down visualization views to provide transparency and feedback in a true Six-Sigma fashion. Dynamic navigation provides rapid drill down and analysis into specific information captured at each organizational level and every process stage.
Anthera Pharmaceuticals, Inc.  
  Anthera Pharmaceuticals is a start-up pharmaceutical company focused on the in-licensing of promising clinical candidates for the treatment of serious respiratory and inflammatory diseases. Anthera has identified four clinical stage products which have the potential to address a variety of these target diseases including: Acute Lung Injury, Cystic Fibrosis, COPD, Asthma, and idiopathic pulmonary fibrosis.
Coapt Systems, Inc.  
  Coap Systems Inc. develops bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures. Featuring MultiPoint™ technology, their products enable physician to reliably place and shape soft tissue without sutures, pins, or screws.
  Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera’s lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.
  EndoVx's approach has showed effective long term weight loss in a prior human surgical study. Their proprietary procedure is quick, bloodless, and done on an out-patient basis. EndoVx is moving forward to demonstrate the performance of the system and generate additional clinical data. Lanfear Capital is a Board Observer of the company. EndoVx
LanfearCapital :: 555 Bryant Street, #266 Palo Alto, CA 94301 :: 650.325.2500